Olav Dalgard
Olav Dalgard
Professor of medicine, University of Oslo
Verified email at
Cited by
Cited by
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017
EASL recommendations on treatment of hepatitis C 2018
European Association for The Study of The Liver
Journal of hepatology 69 (2), 461-511, 2018
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, ...
Liver International 31, 30-60, 2011
EASL recommendations on treatment of hepatitis C: final update of the series☆
JM Pawlotsky, F Negro, A Aghemo, M Berenguer, O Dalgard, G Dusheiko, ...
Journal of hepatology 73 (5), 1170-1218, 2020
Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial
GJ Dore, F Altice, AH Litwin, O Dalgard, EJ Gane, O Shibolet, ...
Annals of internal medicine 165 (9), 625-634, 2016
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
O Dalgard, K Bjøro, KB Hellum, B Myrvang, S Ritland, K Skaug, ...
Hepatology 40 (6), 1260-1265, 2004
CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients
V Béziat, O Dalgard, T Asselah, P Halfon, P Bedossa, A Boudifa, ...
European journal of immunology 42 (2), 447-457, 2012
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
J Grebely, O Dalgard, B Conway, EB Cunningham, P Bruggmann, ...
The lancet Gastroenterology & hepatology 3 (3), 153-161, 2018
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
C Axfors, AM Schmitt, P Janiaud, J van’t Hooft, S Abd-Elsalam, EF Abdo, ...
Nature communications 12 (1), 2349, 2021
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
O Dalgard, K Bjøro, H Ring‐Larsen, E Bjornsson, M Holberg‐Petersen, ...
Hepatology 47 (1), 35-42, 2008
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
MS Sulkowski, C Cooper, B Hunyady, J Jia, P Ogurtsov, ...
Nature reviews Gastroenterology & hepatology 8 (4), 212-223, 2011
HCV epidemiology in high-risk groups and the risk of reinfection
H Midgard, A Weir, N Palmateer, VL Re III, JA Pineda, J Macías, ...
Journal of hepatology 65 (1), S33-S45, 2016
Recommendations for the management of hepatitis C virus infection among people who inject drugs
J Grebely, G Robaeys, P Bruggmann, A Aghemo, M Backmund, ...
International Journal of Drug Policy 26 (10), 1028-1038, 2015
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
A Moghaddam, E Melum, N Reinton, H Ring‐Larsen, H Verbaan, K Bjøro, ...
Hepatology 53 (3), 746-754, 2011
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm–volume 2
A Hatzakis, V Chulanov, AC Gadano, C Bergin, Z Ben‐Ari, J Mossong, ...
Journal of viral hepatitis 22, 26-45, 2015
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
AD Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, ...
The lancet Gastroenterology & hepatology 3 (2), 125-133, 2018
Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy
O Dalgard, K Bjøro, K Hellum, B Myrvang, T Bjøro, E Haug, H Bell
Journal of internal medicine 251 (5), 400-406, 2002
Hepatitis C reinfection after sustained virological response
H Midgard, B Bjøro, A Mæland, Z Konopski, H Kileng, JK Damås, ...
Journal of hepatology 64 (5), 1020-1026, 2016
Historical epidemiology of hepatitis C virus (HCV) in select countries–volume 2
V Saraswat, S Norris, RJ De Knegt, JF Sanchez Avila, M Sonderup, ...
Journal of viral hepatitis 22, 6-25, 2015
Recommendations for the management of hepatitis C virus infection among people who inject drugs
G Robaeys, J Grebely, S Mauss, P Bruggmann, J Moussalli, A De Gottardi, ...
Clinical Infectious Diseases 57 (suppl_2), S129-S137, 2013
The system can't perform the operation now. Try again later.
Articles 1–20